ResMed Study Claims Nearly A Billion People Worldwide Have Sleep Apnea
A new multinational analysis by ResMed showed that the number of people with sleep apnea is 10 times higher than previous estimates by the World Health Organization, raising the need for developing strategies to raise awareness of the disease and diagnose and treat the disease.
You may also be interested in...
ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.
In this edition of Device Week, Medtech Insight's managing editor Marion Webb talks with deputy editor Reed Miller about his recent story on Abiomed's plan to counter unfavorable studies of its Impella heart pump.
[Editor's note: This article was updated on 14 February 2020 to clarify that Abiomed has invested more than $100m over the past five years in clinical research on the Impella heart pump platform. Abiomed has not committed to spend another $100m on new physician education and communication programs.]
Start-Up Spotlight: BioIntelliSense Launches New FDA-Cleared BioSticker For Remote Monitoring Of Patients' Vital Signs
BioIntelliSense is getting ready to trial its newly FDA-cleared BioSticker in patients at Colorado-based hospital network UCHealth for remote monitoring of vital signs.